Reduction of Phosphorylated Tau during Memantine Treatment of Alzheimer’s Disease

Publisher： Karger

E-ISSN： 1421-9824|24|4|247-252

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.24, Iss.4, 2007-08, pp. : 247-252

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CSF Biomarkers for Alzheimer’s Disease: Levels of β-Amyloid, Tau, Phosphorylated Tau Relate to Clinical Symptoms and Survival

By  

Dementia and Geriatric Cognitive Disorders, Vol. 21, Iss. 3, 2006-02 ,pp. : 131-138

Karger

Access to resources Recommend Favorite

Regional Analysis of Differently Phosphorylated Tau Proteins in Brains from Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 17, Iss. 3, 2004-03 ,pp. : 122-131

Karger

Access to resources Recommend Favorite

Specific Functional Effects of Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 18, Iss. 2, 2004-08 ,pp. : 227-232

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite